Valneva Says Its Covid Vaccine Beats AstraZeneca’s. Shares Are Surging.

Valneva Says Its Covid Vaccine Beats AstraZeneca’s. Shares Are Surging.
·2 min read

American depositary receipts of French biotech Valneva are up more than 30% after the firm said its vaccine has stronger immune response and fewer side-effects than AstraZeneca's.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting